Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Breast Cancer

Free Subscription Articles published in Lancet Oncol Retrieve available abstracts of 41 articles: HTML format

Single Articles

May 2025
1. HASSAN H, Allen I, Rahman T, Allen S, et al
   Long-term health outcomes of bilateral salpingo-oophorectomy in BRCA1 and BRCA2 pathogenic variant carriers with personal history of breast cancer: a retrospective cohort study using linked electronic health records.
   Lancet Oncol. 2025 May 7:S1470-2045(25)00156.
   PubMed     Abstract available
   
   
   
2. BLONDEAUX E, Sonnenblick A, Agostinetto E, Bas R, et al
   Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study.
   Lancet Oncol. 2025 May 7:S1470-2045(25)00152.
   PubMed     Abstract available
   
   
   
3. ESCRIVA-DE-ROMANI S, Cejalvo JM, Alba E, Friedmann J, et al
   Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single-arm, phase 2a study.
   Lancet Oncol. 2025 May 5:S1470-2045(25)00140.
   PubMed     Abstract available
   
   
   
4. JENSEN MB, Torpe E, Teunissen Z, Taarnhoj G, et al
   Outcomes based on risk-adapted adjuvant therapy in postmenopausal women with early breast cancer: a nationwide, prospective cohort study by the Danish Breast Cancer Group.
   Lancet Oncol. 2025;26:654-662.
   PubMed     Abstract available
   
   
   
5. KUEMMEL S, Graeser M, Schmid P, Reinisch M, et al
   Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trial.
   Lancet Oncol. 2025;26:629-640.
   PubMed     Abstract available
   
   
   
6. GRUBER K
   Monstrosity of Tiny Tumours: an artist's journey through breast cancer.
   Lancet Oncol. 2025;26:558.
   PubMed    
   
   
   March 2025
7. DEVI S
   Projected global rise in breast cancer incidence and mortality by 2050.
   Lancet Oncol. 2025 Mar 6:S1470-2045(25)00136.
   PubMed    
   
   
   
8. ZDENKOWSKI N, Kuper-Hommel MJJ, Niman SM, Francis PA, et al
   Timing of nivolumab with neoadjuvant carboplatin and paclitaxel for early triple-negative breast cancer (BCT1902/IBCSG 61-20; Neo-N): a non-comparative, open-label, randomised, phase 2 trial.
   Lancet Oncol. 2025;26:367-377.
   PubMed     Abstract available
   
   
   
9. MAGSANOC-ALIKPALA MJK, Ylanan AMD, Rivera-Montales C, Magsanoc JM, et al
   Breast cancer survivor-led patient advocacy: the ICanServe experience from the Philippines.
   Lancet Oncol. 2025;26:287-289.
   PubMed    
   
   
   
10. GONCALVES A, de Nonneville A
    Tailoring chemoimmunotherapy de-escalation in early-stage triple-negative breast cancer.
    Lancet Oncol. 2025;26:273-274.
    PubMed    
    
    
    February 2025
11. AHN HK, Kim JY, Lee KH, Kim GM, et al
    Palbociclib plus endocrine therapy versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (Young-PEARL): overall survival analysis of a randomised, open-label, phase 2 study.
    Lancet Oncol. 2025 Feb 17:S1470-2045(25)00006.
    PubMed     Abstract available
    
    
    
12. MUNZONE E, Valenza C
    Tailoring the treatment of premenopausal patients with breast cancer.
    Lancet Oncol. 2025 Feb 17:S1470-2045(25)00060.
    PubMed    
    
    
    
13. BONNEFOI H, Lerebours F, Pulido M, Arnedos M, et al
    Darolutamide or capecitabine in triple-negative, androgen receptor-positive, advanced breast cancer (UCBG 3-06 START): a multicentre, non-comparative, randomised, phase 2 trial.
    Lancet Oncol. 2025 Feb 17:S1470-2045(24)00737.
    PubMed     Abstract available
    
    
    
14. SRIDHAR N, Ueno NT
    Navigating the androgen receptor landscape in triple-negative breast cancer.
    Lancet Oncol. 2025 Feb 17:S1470-2045(25)00029.
    PubMed    
    
    
    
15. VENKATESAN P
    Largest trial of AI in breast cancer screening launched.
    Lancet Oncol. 2025 Feb 13:S1470-2045(25)00080.
    PubMed    
    
    
    
16. CASASSUS B
    Law to extend free medical treatment for breast cancer in France.
    Lancet Oncol. 2025 Feb 6:S1470-2045(25)00069.
    PubMed    
    
    
    January 2025
17. LI L
    FNAB samples with the STRAT4 assay for breast cancer diagnosis.
    Lancet Oncol. 2025;26:e9.
    PubMed    
    
    
    
18. NG DL, Van Loon K, Weidler J, Bates M, et al
    FNAB samples with the STRAT4 assay for breast cancer diagnosis - Authors' reply.
    Lancet Oncol. 2025;26:e10.
    PubMed    
    
    
    December 2024
19. GRUBER K
    Pesticide exposure and increased risk of breast cancer for women in rural Brazil.
    Lancet Oncol. 2024 Dec 19:S1470-2045(24)00726.
    PubMed    
    
    
    
20. HENRY NL
    Optimising therapy and avoiding overtreatment in breast cancer.
    Lancet Oncol. 2024 Dec 11:S1470-2045(24)00707.
    PubMed    
    
    
    
21. MEATTINI I, De Santis MC, Visani L, Scorsetti M, et al
    Single-modality endocrine therapy versus radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early breast cancer (EUROPA): a preplanned interim analysis of a phase 3, non-inferiority, randomised trial.
    Lancet Oncol. 2024 Dec 11:S1470-2045(24)00661.
    PubMed     Abstract available
    
    
    
22. RUGO HS, Lerebours F, Ciruelos E, Drullinsky P, et al
    Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.
    Lancet Oncol. 2024;25:e629-e638.
    PubMed     Abstract available
    
    
    November 2024
23. CHEN XC, Jiao DC, Qiao JH, Wang CZ, et al
    De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial.
    Lancet Oncol. 2024 Nov 26:S1470-2045(24)00581.
    PubMed     Abstract available
    
    
    
24. LUND M, Corn G, Jensen MB, Petersen T, et al
    Ischaemic cardiotoxicity of aromatase inhibitors in postmenopausal patients with early breast cancer in Denmark: a cohort study of real-world data.
    Lancet Oncol. 2024;25:1496-1506.
    PubMed     Abstract available
    
    
    
25. OLIVEIRA M, Pominchuk D, Nowecki Z, Hamilton E, et al
    Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial.
    Lancet Oncol. 2024;25:1424-1439.
    PubMed     Abstract available
    
    
    October 2024
26. NG DL, Vuhahula E, Kimambo AH, Ndayisaba MC, et al
    Xpert Breast Cancer STRAT4 Assay using fine-needle aspiration biopsy samples in a resource-constrained setting: a prospective diagnostic accuracy study.
    Lancet Oncol. 2024 Oct 3:S1470-2045(24)00456.
    PubMed     Abstract available
    
    
    September 2024
27. OLIVEIRA M, Rugo HS, Howell SJ, Dalenc F, et al
    Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial.
    Lancet Oncol. 2024;25:1231-1244.
    PubMed     Abstract available
    
    
    
28. KOLBERG HC, Kolberg-Liedtke C
    Who does not benefit from whole-breast radiotherapy and how to find them?
    Lancet Oncol. 2024;25:1110-1111.
    PubMed    
    
    
    
29. DE BONIFACE J, Appelgren M, Szulkin R, Alkner S, et al
    Completion axillary lymph node dissection for the identification of pN2-3 status as an indication for adjuvant CDK4/6 inhibitor treatment: a post-hoc analysis of the randomised, phase 3 SENOMAC trial.
    Lancet Oncol. 2024;25:1222-1230.
    PubMed     Abstract available
    
    
    August 2024
30. GOURD E
    Disappointment facing patients with breast cancer as trastuzumab deruxtecan too expensive for NHS.
    Lancet Oncol. 2024 Aug 8:S1470-2045(24)00446.
    PubMed    
    
    
    
31. WILLIAMS LJ, Kunkler IH, Taylor KJ, Dunlop J, et al
    Postoperative radiotherapy in women with early operable breast cancer (Scottish Breast Conservation Trial): 30-year update of a randomised, controlled, phase 3 trial.
    Lancet Oncol. 2024 Aug 7:S1470-2045(24)00347.
    PubMed     Abstract available
    
    
    
32. BARRIO AV
    Time to abandon axillary lymph node dissection in early-stage breast cancer.
    Lancet Oncol. 2024 Aug 6:S1470-2045(24)00385.
    PubMed    
    
    
    July 2024
33. OFUYA M
    Overcoming barriers to early breast cancer presentation in Nigeria.
    Lancet Oncol. 2024;25:840.
    PubMed    
    
    
    
34. GOURD E
    Olufunmilayo Olopade-preventive oncologist using genetics to fight breast cancer in high-risk populations.
    Lancet Oncol. 2024;25:839.
    PubMed    
    
    
    
35. PELLERIN R
    New Canadian draft breast screening guidelines issued.
    Lancet Oncol. 2024;25:836.
    PubMed    
    
    
    May 2024
36. FEHM T, Cottone F, Dunton K, Andre F, et al
    Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial.
    Lancet Oncol. 2024;25:614-625.
    PubMed     Abstract available
    
    
    April 2024
37. VAN DER VOORT A, Louis FM, van Ramshorst MS, Kessels R, et al
    MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II-III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study.
    Lancet Oncol. 2024 Apr 5:S1470-2045(24)00104.
    PubMed     Abstract available
    
    
    
38. BROWNE IM, Andre F, Chandarlapaty S, Carey LA, et al
    Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer.
    Lancet Oncol. 2024;25:e139-e151.
    PubMed     Abstract available
    
    
    
39. LAYMAN RM, Han HS, Rugo HS, Stringer-Reasor EM, et al
    Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study.
    Lancet Oncol. 2024;25:474-487.
    PubMed     Abstract available
    
    
    March 2024
40. TOI M, Kinoshita T, Benson JR, Jatoi I, et al
    Non-surgical ablation for breast cancer: an emerging therapeutic option.
    Lancet Oncol. 2024;25:e114-e125.
    PubMed     Abstract available
    
    
    October 2023
41. MUTTER RW, Giri S, Fruth BF, Remmes NB, et al
    Conventional versus hypofractionated postmastectomy proton radiotherapy in the USA (MC1631): a randomised phase 2 trial.
    Lancet Oncol. 2023;24:1083-1093.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.